You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》富瑞上調君實生物(01877.HK)目標價至45元 評級「持有」
富瑞發表報告指,君實生物(01877.HK)完成有關新冠口服藥VV116的第三期臨床研究報告,並進行針對該藥物與奈瑪特韋片/利托那韋片組合藥物(Paxlovid)治療輕至中度新冠病毒感染患者的對比測試。 該行指,報告顯示服用VV116藥物的新冠陽性患者恢復時間為4日,而Paxlovid則為5日,惟目前仍有更多研究進行當中,該行預計今年首季或次季的稍後時間會有更多數據出現,以支持內地市場的審批。 據報告指出,該藥物現在烏茲別克斯坦有售,每個療程185美元。 該行將君實生物目標價由40元上調至45元,維持其評級為「持有」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account